Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.45 |
| ▸ | AKT1S1 | Q96B36 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460909 | 0.86 | P2RX7 (0.48) | P2RX7RPS6KB1AKT1S1OPRM1OPRD1 | |
| SCHEMBL12278785 | 0.84 | OPRL1 (0.48) | P2RX7RPS6KB1OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2405292 | 0.83 | OPRL1 (0.47) | P2RX7RPS6KB1OPRM1OPRD1OPRK1 | |
| SCHEMBL16460365 | 0.82 | P2RX7 (0.51) | P2RX7RPS6KB1OPRM1OPRD1OPRK1 | |
| SCHEMBL15129216 | 0.82 | RPS6KB1 (0.52) | P2RX7RPS6KB1AKT1S1 | |
| SCHEMBL16461381 | 0.82 | RPS6KB1 (0.50) | P2RX7RPS6KB1AKT1S1OPRM1 | |
| SCHEMBL16461973 | 0.82 | RPS6KB1 (0.50) | P2RX7RPS6KB1AKT1S1 | |
| SCHEMBL16395501 | 0.81 | RPS6KB1 (0.52) | P2RX7RPS6KB1 | |
| SCHEMBL16395576 | 0.81 | RPS6KB1 (0.52) | P2RX7RPS6KB1 | |
| SCHEMBL12701169 | 0.81 | RPS6KB1 (0.52) | P2RX7RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210085667-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20200405706-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20190307766-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3536689-A1 | 2-(CYCLIC AMINEETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MindImmune Therapeutics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2906549-B1 | N-(2-(CYCLIC AMINE)ETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MINDIMMUNE THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10124010-B2 | Cyclic amines | MINDIMMUNE THERAPEUTICS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180177793-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9861639-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2018-01-09 | — | — | US | disclosed |
| US-20170128460-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2017-05-11 | — | — | US | disclosed |
| US-9593105-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2017-03-14 | — | — | US | disclosed |
| US-20170008898-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| US-9415055-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2016-08-16 | — | — | US | disclosed |
| US-20150306114-A1 | Cyclic Amines | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| EP-2906549-A2 | CYCLIC AMINES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9108938-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2015-08-18 | — | — | US | disclosed |
| US-20140107335-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057080-A2 | CYCLIC AMINES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405706-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885RPS6KB1 1965/4885AKT1S1 1737/4885 |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885RPS6KB1 1965/4885AKT1S1 1737/4885 |
| US-20170008898-A1 | Cyclic Amines | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
| US-20150306114-A1 | Cyclic Amines | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885RPS6KB1 1965/4885AKT1S1 1737/4885 |
| US-20190307766-A1 | CYCLIC AMINES | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
| US-20140107335-A1 | Cyclic Amines | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
| US-20210085667-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885RPS6KB1 1965/4885AKT1S1 1737/4885 |
| US-10124010-B2 | Cyclic amines | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
| US-20180177793-A1 | CYCLIC AMINES | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
| US-20170128460-A1 | Cyclic Amines | P2RX7, ADORA2A, P2RX2 | P2RX7 1/4885RPS6KB1 2290/4885AKT1S1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.